What Supplement Brands Can Legally Claim in India: FSSAI Nutra Rules Simplified
Most supplement marketing trouble is not caused by rule-breakers. It is caused by founders who never got a plain-language map of rules written across half a dozen regulations. This is that map — educational, not legal advice.
In short: Your licence decides your rulebook: FSSAI's food-law framework (health supplements and nutraceuticals) or the AYUSH drugs regime — different ceilings, different labels. Under FSSAI, nutrition claims and permitted function claims are workable territory; disease treatment, prevention and cure claims are prohibited, and the DMR Act bans advertising remedies for a schedule of conditions outright. Build a claims process — approved library, substantiation file, counsel sign-off — because enforcement arrives through notices, marketplaces delistings and ad rejections. Educational content only: take decisions with qualified counsel.
This article is educational marketing commentary for brand founders, not legal advice. Regulations change and their application depends on your product, licence and labels — make claim decisions with qualified food-law counsel.
Which rulebook governs your product — food, nutra or AYUSH?
Everything downstream depends on a single fact: what licence your product sells under. Most modern supplement formats — proteins, gummies, capsules with vitamins, minerals and botanicals — sell as food under the FSS Act, governed by FSSAI’s framework for health supplements and nutraceuticals: the 2022 regulations covering health supplements, nutraceuticals, foods for special dietary use and related categories, which replaced the 2016 version. Products licensed as Ayurvedic, Siddha or Unani medicines sit under the drugs framework instead, with their own claim logic — the territory of the AYUSH playbook. The same ashwagandha capsule can exist in either regime depending on licensing, with different permitted claims, labels and enforcement paths. Founders who never establish this fact end up quoting rules that do not apply to them — in both directions.
What kinds of claims does the FSSAI framework recognise?
India’s advertising-and-claims regulations for food (2018) plus the nutraceutical rules create a hierarchy worth internalising as a ladder of increasing scrutiny:
| Claim type | What it looks like | Practical status |
|---|---|---|
| Nutrition content claims | “High in protein”, “source of vitamin C”, “zero added sugar” | Workable when the label maths meets the defined thresholds |
| Comparative claims | “30% less sugar than…” | Permitted with a fair, stated basis of comparison |
| Function / nutrient-function claims | “Vitamin D contributes to normal bone maintenance” | Territory exists for recognised nutrient-function statements tied to what the product actually contains |
| Disease-risk-reduction claims | “Reduces risk of…” | Heavily restricted; approval-gated — not a self-serve option |
| Treatment / cure / prevention claims | “Cures”, “treats”, “prevents”, disease names | Prohibited for foods and supplements, full stop |
Above the whole ladder sits the Drugs and Magic Remedies (Objectionable Advertisements) Act, which bans advertising remedies for a schedule of diseases and conditions regardless of category — and ASCI’s code, which polices misleading health advertising across all of it. The compressed version: describe what the product contains and the recognised roles of those nutrients; never what it will fix.
As of 2026: the enforcement climate is not theoretical. FSSAI has run periodic enforcement and relabelling drives in the supplements category, and ASCI’s annual complaints reports have repeatedly ranked healthcare, Ayush and wellness advertising among the most-violative sectors they process — with a large share of flagged ads involving unsubstantiated health claims. Platform enforcement is stricter still: Meta, Google and the marketplaces reject or delist for phrasing regulators might never see.
What can you say on the label versus in the ad?
The label is the stricter master, and the ad may not exceed it. Labels under the nutraceutical framework carry defined requirements — the mandated warnings and statements (including that such products are not for medicinal use, plus category-specific advisories), permitted ingredient lists per the regulation’s schedules, and dosage boundaries tied to recommended daily allowances rather than pharmacological levels. The advertising layer then inherits everything the label established: an ad cannot claim what the dossier and label do not support, and adds its own rules — ASCI’s code, disclosure requirements for influencer content, and the platforms’ health policies that reject legal copy anyway, the machinery described in why Meta rejects compliant ads. A useful discipline: treat the label dossier as the single source of truth, and require every ad claim to cite its line in that dossier. If the citation hunt takes longer than writing the ad, the claim probably should not run.
What gets supplement brands into trouble most often?
- 1. Implied disease claims. “Supports sugar control”, “fights infection season” — implication is the standard ASCI catch, not the word “cures”.
- 2. Testimonials that claim what the brand cannot. A customer saying “it cured my…” in your ad is your claim now.
- 3. Borrowed foreign language. US DSHEA-style structure-function phrasing pasted into Indian ads — a different legal system’s vocabulary, imported with none of its footing (relevant if you also export, per the US & UAE guide).
- 4. Influencer improvisation. Under ASCI’s guidelines a creator’s health claim is the brand’s advertisement; unscripted enthusiasm is unpriced liability.
- 5. Before-after theatre. Visual claims are claims — and platform classifiers catch them faster than regulators do.
- 6. The landing-page gap. Compliant ads pointing at PDPs full of cure-adjacent reviews and pop-ups; enforcement and platform review read the whole funnel.
How do you build a claims process that scales?
The brands that stay out of trouble do not memorise regulations; they run a system. 1. An approved-claims library: every permitted phrase, per product, with its substantiation reference — the single document ads, PDPs, packaging and creator briefs all draw from. 2. A substantiation file: the label dossier, test reports and formulation basis behind each claim, maintained before anyone asks. 3. Counsel sign-off at the boundaries: new claim territory gets legal review once, then enters the library — instead of fifty ad-hoc opinions a year. 4. Creative guardrails: writers work from the library plus the evidence-over-outcome angles that need no restricted claims at all. 5. An audit trail: who approved what, when — because notices ask. The process pays for itself the first time a rejection wave or marketplace delisting does not happen; the agency-side version of this machinery is what we described in the herbal agency shortlist, and the category context lives on our nutrition and wellness page. Label-side food rules have their own guide in FSSAI and label compliance for D2C food.
Reminder: educational commentary only — regulations, schedules and enforcement practice evolve. Take specific claim decisions with qualified counsel and your regulatory documentation.
Frequently asked questions
What claims can a supplement brand legally make in India?
Under FSSAI's framework, workable territory includes nutrition content claims ('high in protein'), fair comparative claims, and recognised nutrient-function statements tied to what the product contains. Disease treatment, prevention and cure claims are prohibited for supplements, disease-risk-reduction claims are approval-gated, and the Drugs and Magic Remedies Act bans advertising remedies for scheduled conditions entirely. This is educational commentary, not legal advice — specifics depend on your product and licence.
What is the difference between a nutraceutical and an Ayurvedic product legally?
Licence, not ingredient. The same botanical can sell as a nutraceutical under FSSAI's food-law framework — with food-style claims, labels and RDA-bounded dosages — or as a licensed Ayurvedic (ASU) medicine under the drugs framework, with a different claims logic and enforcement path. Which regime you are in decides everything about what you may say, so it is the first fact to establish before writing any marketing.
Can supplements say 'boosts immunity' in Indian advertising?
Vague boost-language is exactly the territory where most enforcement and ASCI complaints happen, because it implies a health outcome the dossier usually cannot substantiate. Safer ground is precise, supported phrasing tied to recognised nutrient functions of ingredients actually present at meaningful levels. The honest test: can the claim cite its exact line in your label dossier? If not, rewrite it — and confirm boundaries with counsel.
Who enforces supplement advertising rules in India?
Several layers at once: FSSAI and state food-safety machinery for products and labels, ASCI for advertising complaints, and the consumer-protection framework for misleading ads — plus the private enforcers brands feel first: Meta and Google ad review and marketplace delisting policies, which act faster and more often than any regulator. Building one claims process that satisfies the strictest layer is cheaper than fighting each separately.
Is this article legal advice for supplement brands?
No. It is a plain-language educational map for founders and marketers. Regulations, schedules and enforcement practice change, and their application turns on your specific product, licence, formulation and labels. Use this to ask better questions, and make actual claim decisions with qualified food-law counsel.
Turn the rules into a growth system
Book a free Growth Audit and we will review your claims exposure across ads, PDPs and creator content — and show you the compliant angles that still sell. Best fit: brands spending ₹3 lakh+ a month on ads.
Book a Growth Audit →